CONTRACEPTION WITH FOLATES: NEW ASPECTS OF THE PROBLEM
https://doi.org/10.21518/2079-701X-2018-7-28-31
Abstract
Recently, the use of drospirenone-containing microdosed hormonal contraceptives containing folates has come at an opportune time. The common use of these contraceptives is associated with not only high efficacy and acceptability, but also with a positive effect on the symptoms of premenstrual syndrome, which is mediated by impact on the central nervous system. Drospirenonecontaining COCs are also known as products leading to a reduction in sebum excretion rates, which makes it possible to use them in acne therapy. Metafolin as part of microdosed hormonal contraceptive Yaz® plus compensates for the folate concentration required to prevent neural tube defects in the fetus in 27–30 days of pregnancy to some extent. Consequently, the use of drospirenone-containing hormonal contraceptives with folates provides not only a contraceptive, but also a therapeutic effect when fluid is retained in the body tissues. Thus, Yaz® plus product is indicated for use not only for contraceptive, but also for therapeutic purposes, as indicated in the patient information leaflet.
About the Authors
A. N. Mgeryan
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. N. Prilepskaya
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Bale J, Stoll B, Lucas A et al. Reducing Birth Defects: Meeting the Challenge in the Developing World. Washington, DC: The National Academies Press, 2003.
2. Zohra S Lassi, Zulfiqar A Bhutta. International Journal of Women’s Health, 2012, 4: 185–190.
3. Finan A, Clarke TA, Matthews TG et al. Strategies for reduction ofneonatal mortality. Ir J Med Sci, 1999, 168(4): 265–267.
4. World Health Organisation. The global burden of disease: 2004 update. 2008. Available from: http: //www.who.int/healthinfo/global_burden_ disease/GBD_report_2004update_full.pdf. Accessed on December 15, 2011.
5. Van der Linden IJM, Afman LA, Heil SG, Blom HJ. Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutri Soc, 2006, 65(02): 204–215.
6. Wasserman CR, Shaw GM, Selvin S et al. Socioeconomic status, neighbourhood social conditions, and neural tube defects. Am J Public Health, 1998, 88(11): 1674–1680.
7. Vrijheid M, Dolk H, Stone D, Abramsky L, Alberman E, Scott JES. Socioeconomic inequalities in risk of congenital anomaly. Arch Dis Child, 2000, 82(5): 349–352.
8. Chango A, Emery-Fillon N, de Courcy GP et al. A polymorphism (80G-. A) in the reduced folate carrier gene and its associations With folate status and homocysteinemia. Mol Genet Metab, 2000, 70(4): 310–315.
9. Van Beynum IM, Kapusta L, Den Heijer M, et al. Maternal MTHFR 677C. T is a risk factor for congenital heart defects: effect modification by per-iconceptional folate supplementation. Eur Heart J, 2006, 27(8): 981–987.
10. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C, 2004; 125C: 12–21.
11. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr. 2007, 85(1): 285–288.
12. De Benoist B. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull, 2008, 29(Suppl 2): 238–244.
13. Refsum H, Smith AD. Are we ready for mandatory fortification with vitamin B-12? Am J Clin Nutr, 2008, 88(2): 253–254.
14. Patrick TE, Powers RW, Daftary AR, Ness RB, Roberts JM. Homocysteine and folic acid are inversely related in black women with preeclampsia. Hypertension, 2004, 43(6): 1279–1282.
15. Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr, 2006, 83(5): 993–1016.
16. De Benoist B. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull, 2008, 29(Suppl 2): 238– 244.
17. Morris J.K., Wald N.J. Prevalence of neural tube defect pregnancies in England and Wales from 1964 to 2004. J Med Screen, 2007, 14(2): 55–59.
18. Wald N, Sneddon J, Densem J et al. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet, 1991, 338(8760): 131–137.
19. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med, 1992, 327(26): 1832–1835.
20. De-Regil LM, Fernandez-Gaxiola AC, Dowswell T et al. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Sys Reviews, 2010.
21. Oelkers W. Drospirenone – a new progestogen with antimineralocorticoid activity, resembling-natural progesterone. Eur. J. Contracept. Reprod. Health Care, 2000, 5(Suppl. 3): 17–24.
22. Fruzzetti F, Lello S, Lazzarini V et al. The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception, 2007, 75: 199–203.
23. Fruzzetti F, Lazzarini V, Ricci C et al. Effect of an oral contraceptive containing 30 μg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception, 2007, 76: 190–194.
24. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care, 2000, 5: 25–34.
25. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg + ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg + ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception, 2009, 80: 445–451.
26. Hernadi L, Marr J, Trummer D. et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol20 mcg in a 24/4-day regimen. Contraception, 2009, 80: 18–24.
27. Willis SA, Kuehl TJ, Spiekerman AM et al. Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception, 2006, 74: 100– 103.
28. Rapkin AJ, Shelley N, Sorger NS et al. Drospirenone/ethinylestradiol. Drugs Today (Barc.), 2008, 44: 133–145.
29. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med, 2008, 53(Suppl. 9): 729–741.
30. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low dose oral contraceptive-with drospirenone in premenstrual dysphoricdis-order. Obstet Obstet. Gynecol., 2005, 106: 492– 501.
31. Andreeva EN, Grigoryan OR, Sheremetyeva EV. Effect of folate-containing combined oral contraceptives on homocysteine levels in women with polycystic ovary syndrome. Problemy Reproduktsii, 2014, 2: 27-31.
32. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3 mg/20 μg (24/4 day regimen): a review of itsuse in contraception, premenstrual dysphoricdisorder and moderate acne vulgaris. Drugs, 2007, 67: 1749–1765.
33. Contraceptive guide. Edited by Prof. Prilepskaya VN. 4th edition, 2017.
34. Maloney JM, Kunz M, Lee-Sugh S et al. Drosperinone 3 mg/ethinylestradiol 20 μgCOC in the treatment of acne vulgaris: lesion count, ISGA. Presented at: 55th AnnualClinical Meeting of the American College ofObstetricians and Gynaecologists. San Diego, CA, USA, 5–9 May, 2007.
35. Marr AJ, Sampson-Landers C, Diefenbach K, Trummer D, Bart S, Blode H. Folate and homo-cysteine levels after 24 weeks administration of Yaz + levomefolate calcium 451 mg. Presented at: The 11th Congress of the European Society of Contraception and Reproductive Health. The Hague, The Netherlands, 19–22 May 2010 (Abstract P178).
36. Diefenbach K, Trummer D, Ebert F, Lissy M, Rohde B, Blode H. Changes in folatelevels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration. Presented at: The 11th Congress of the European Society of Contraception and Reproductive Health. The Hague, The Netherlands, 19–22 May 2010 (Abstract P176).
37. Bart SS, Marr J, Diefenbach K et al. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, doubleblind, active-controlled, parallel-group, US-based multicenter study. Contraception, 2010, 85(1): 42–50.
Review
For citations:
Mgeryan AN, Prilepskaya VN. CONTRACEPTION WITH FOLATES: NEW ASPECTS OF THE PROBLEM. Meditsinskiy sovet = Medical Council. 2018;(7):28-31. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-28-31
Views:
714
Email this article 